Works about BORTEZOMIB
Results: 1565
A novel mechanism in regulating drug sensitivity, growth, and apoptosis of bortezomib-resistant multiple myeloma cells: the USP4/KLF2/HMGA2 cascade.
- Published in:
- Journal of Orthopaedic Surgery & Research, 2025, v. 20, n. 1, p. 1, doi. 10.1186/s13018-025-05537-1
- By:
- Publication type:
- Article
Effects of c-Kit Receptor, AKT, and NF-κB Inhibitors on Immune Evasion in Multiple Myeloma Cells.
- Published in:
- Iranian Journal of Allergy, Asthma & Immunology, 2025, v. 24, n. 1, p. 89, doi. 10.18502/ijaai.v24i1.18024
- By:
- Publication type:
- Article
Time-dependent recovery of renal impairment in patients with newly diagnosed multiple myeloma.
- Published in:
- Annals of Hematology, 2025, v. 104, n. 1, p. 573, doi. 10.1007/s00277-025-06201-8
- By:
- Publication type:
- Article
A retrospective analysis of autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation for transfusion-dependent β-thalassemia: focus on T and B lymphocyte reconstitution.
- Published in:
- Annals of Hematology, 2025, v. 104, n. 1, p. 721, doi. 10.1007/s00277-024-06157-1
- By:
- Publication type:
- Article
Early dFLC response by C1D7 predicts complete hematologic response in systemic AL amyloidosis.
- Published in:
- Annals of Hematology, 2025, v. 104, n. 1, p. 617, doi. 10.1007/s00277-024-06077-0
- By:
- Publication type:
- Article
Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study.
- Published in:
- Annals of Hematology, 2025, v. 104, n. 1, p. 515, doi. 10.1007/s00277-024-05958-8
- By:
- Publication type:
- Article
Effect of proteasome inhibitors on canine lymphoma cell response to CHOP chemotherapy in vitro.
- Published in:
- Veterinary & Comparative Oncology, 2024, v. 22, n. 1, p. 96, doi. 10.1111/vco.12957
- By:
- Publication type:
- Article
Mussel-Inspired Electrospun Smart Magnetic Nanofibers for Hyperthermic Chemotherapy.
- Published in:
- Advanced Functional Materials, 2015, v. 25, n. 19, p. 2867, doi. 10.1002/adfm.201500389
- By:
- Publication type:
- Article
Bortezomib is efficacious in the treatment of severe childhood-onset neuropsychiatric systemic lupus erythematosus with psychosis: a case series and mini-review of B-cell immunomodulation in antibody-mediated diseases.
- Published in:
- Clinical Rheumatology, 2023, v. 42, n. 7, p. 1965, doi. 10.1007/s10067-023-06559-y
- By:
- Publication type:
- Article
Development of a Spectrophotometric Method for the Measurement of Kinetic Solubility: Economical Approach to be Used in Pharmaceutical Companies.
- Published in:
- Pharmaceutical Chemistry Journal, 2017, v. 51, n. 6, p. 511, doi. 10.1007/s11094-017-1645-9
- By:
- Publication type:
- Article
Protective Role of Humanin on Bortezomib-Induced Bone Growth Impairment in Anticancer Treatment.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2014, v. 106, n. 3, p. 1, doi. 10.1093/jnci/djt459
- By:
- Publication type:
- Article
Addition of Bcl-2 Inhibitor to MM Regimen Produces Promising Responses in Relapsed/Refractory MM.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 6, p. 258
- Publication type:
- Article
Case: Biomarkers in Multiple Myeloma.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 2, p. 74
- By:
- Publication type:
- Article
In Newly Diagnosed Myeloma Patients, Triplets Preferred.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 1, p. 36
- By:
- Publication type:
- Article
Case Report: Intense Maintenance in a Woman with High-Risk Multiple Myeloma.
- Published in:
- Personalized Medicine in Oncology, 2015, v. 4, n. 1, p. 48
- Publication type:
- Article
Simultaneous Inhibition Of Proteasome And Autophagy Synergistically Enhance Cytotoxicity Of Doxorubicin In Breast Cancer Cells.
- Published in:
- 2022
- By:
- Publication type:
- Abstract
Minimal effect of bortezomib in reducing anti-pig antibodies in human leukocyte antigen-sensitized patients: a pilot study.
- Published in:
- Xenotransplantation, 2013, v. 20, n. 6, p. 429, doi. 10.1111/xen.12052
- By:
- Publication type:
- Article
Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01117-4
- By:
- Publication type:
- Article
CD56 expression predicts response to Daratumumab-based regimens.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01051-5
- By:
- Publication type:
- Article
Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01034-6
- By:
- Publication type:
- Article
BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00955-y
- By:
- Publication type:
- Article
Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00937-0
- By:
- Publication type:
- Article
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00882-y
- By:
- Publication type:
- Article
E-selectin-targeting lipid nanoparticles improve therapeutic efficacy and reduce side effects of bortezomib in multiple myeloma.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00828-4
- By:
- Publication type:
- Article
Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II Study.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00816-8
- By:
- Publication type:
- Article
Prognostic value of extracellular matrix gene mutations and expression in multiple myeloma.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00817-7
- By:
- Publication type:
- Article
Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 11, p. 1, doi. 10.1038/s41408-022-00758-7
- By:
- Publication type:
- Article
Venetoclax ex vivo functional profiling predicts improved progression-free survival.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 8, p. 1, doi. 10.1038/s41408-022-00710-9
- By:
- Publication type:
- Article
Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN.
- Published in:
- 2022
- By:
- Publication type:
- Letter
Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myeloma.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 4, p. 1, doi. 10.1038/s41408-022-00635-3
- By:
- Publication type:
- Article
Early free light chain reduction following treatment initiation predicts favorable outcome in intact immunoglobulin myeloma.
- Published in:
- 2022
- By:
- Publication type:
- Letter
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41408-021-00593-2
- By:
- Publication type:
- Article
Low NCOR2 levels in multiple myeloma patients drive multidrug resistance via MYC upregulation.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 12, p. 1, doi. 10.1038/s41408-021-00589-y
- By:
- Publication type:
- Article
Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 6, p. 1, doi. 10.1038/s41408-021-00510-7
- By:
- Publication type:
- Article
Comprehensive Review of AL amyloidosis: some practical recommendations.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 5, p. 1, doi. 10.1038/s41408-021-00486-4
- By:
- Publication type:
- Article
Racial disparities in patients diagnosed with light chain (AL) amyloidosis.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41408-020-00390-3
- By:
- Publication type:
- Article
VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 11, p. 1, doi. 10.1038/s41408-020-00378-z
- By:
- Publication type:
- Article
Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study.
- Published in:
- 2020
- By:
- Publication type:
- Letter
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 5, p. 1, doi. 10.1038/s41408-020-0311-8
- By:
- Publication type:
- Article
Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 3, p. 1, doi. 10.1038/s41408-020-0298-1
- By:
- Publication type:
- Article
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 2, p. 1, doi. 10.1038/s41408-020-0273-x
- By:
- Publication type:
- Article
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.
- Published in:
- Blood Cancer Journal, 2019, v. 9, n. 12, p. 1, doi. 10.1038/s41408-019-0254-0
- By:
- Publication type:
- Article
In response to: Treatment of patients with multiple myeloma progressing on frontline therapy with lenalidomide, Moreau et al., 2019.
- Published in:
- 2019
- By:
- Publication type:
- Letter to the Editor
Integrated transcriptomics- and structure-based drug repositioning identifies drugs with proteasome inhibitor properties.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-69465-6
- By:
- Publication type:
- Article
Physicochemical stability of bortezomib solutions for subcutaneous administration.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-58473-1
- By:
- Publication type:
- Article
Synergistically Anti-Multiple Myeloma Effects: Flavonoid, Non-Flavonoid Polyphenols, and Bortezomib.
- Published in:
- Biomolecules (2218-273X), 2022, v. 12, n. 11, p. 1647, doi. 10.3390/biom12111647
- By:
- Publication type:
- Article
Metformin Induces Resistance of Cancer Cells to the Proteasome Inhibitor Bortezomib.
- Published in:
- Biomolecules (2218-273X), 2022, v. 12, n. 6, p. 756, doi. 10.3390/biom12060756
- By:
- Publication type:
- Article
The Mucolipin TRPML2 Channel Enhances the Sensitivity of Multiple Myeloma Cell Lines to Ibrutinib and/or Bortezomib Treatment.
- Published in:
- Biomolecules (2218-273X), 2022, v. 12, n. 1, p. 107, doi. 10.3390/biom12010107
- By:
- Publication type:
- Article
Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations.
- Published in:
- Biomolecules (2218-273X), 2022, v. 12, n. 1, p. 51, doi. 10.3390/biom12010051
- By:
- Publication type:
- Article